Vor Biopharma Inc. (VOR)
| Market Cap | 1.08B +321.9% |
| Revenue (ttm) | n/a |
| Net Income | 627.78M |
| EPS | 20.19 |
| Shares Out | 59.16M |
| PE Ratio | 0.91 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 472,841 |
| Open | 18.85 |
| Previous Close | 18.58 |
| Day's Range | 17.97 - 18.87 |
| 52-Week Range | 6.50 - 38.31 |
| Beta | 1.78 |
| Analysts | Strong Buy |
| Price Target | 39.00 (+113.0%) |
| Est. Earnings | Nov 12, 2026 |
About VOR
Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren’s disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products. The company was incorporated in 2015 and... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for VOR stock is "Strong Buy." The 12-month stock price target is $39.0, which is an increase of 113.00% from the latest price.
News
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on October 1, 2026, the...
Vor Bio announces new post hoc analysis from Phase 3 trial on telitacicept
Vor Bio (VOR) announced a new post hoc analysis from the Phase 3 trial conducted in China by its collaborator, RemeGen (REGMF), evaluating telitacicept in adults with generalized myasthenia gravis.
Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis
More than 94% of participants achieved a ≥5-point MG-ADL improvement at Week 48 42% of telitacicept-treated participants achieved minimal symptom expression (MSE) at any time over 48 weeks, increasing...
Vor Biopharma Transcript: Stifel 2026 Virtual Immunology and Inflammation Forum
Telitacicept, a dual BAFF/APRIL inhibitor, is positioned for rapid and durable efficacy in MG, with broad immunoglobulin targeting and a strong safety profile. Market expansion, first-mover advantage, and upcoming data readouts in MG and Sjögren's support a robust commercial outlook.
Vor Biopharma Transcript: Citigroup’s Biopharma Back to School Summit 2026
Telitacicept, a BAFF-APRIL inhibitor, is advancing in phase III trials for myasthenia gravis and Sjögren's disease, with strong enrollment, unique mechanistic differentiation, and significant market potential. Top-line MG data is expected in early 2027, and expansion into ocular MG and other indications is planned.
Vor Biopharma Transcript: Wells Fargo 21st Annual Healthcare Conference
The session highlighted completion of phase III MG trial enrollment, with a key readout expected in 2027, and plans for an ocular MG study. Telitacicept shows robust efficacy and durability, with global trials designed to replicate strong China data. Differentiation is driven by depth, breadth, and convenience of response.
Vor Bio completes enrollment in UPSTREAM MG trial
Vor Bio (VOR) announced the completion of enrollment in UPSTREAM MG, its global Phase 3 registrational trial evaluating telitacicept for the treatment of generalized myasthenia gravis (gMG). Topline r...
Vor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis
Topline results from UPSTREAM MG's 24-week primary endpoint remain on track for first half of 2027 Global Phase 3 ocular myasthenia gravis (oMG) registrational trial, UPSTREAM oMG, broadens telitacice...
Vor Biopharma Slides: Corporate presentation
Vor Biopharma has posted slides in relation to its latest quarterly earnings report, which was published on September 6, 2026.
Vor Bio files automatic mixed securities shelf
16:36 EDT Vor Bio (VOR) files automatic mixed securities shelf
Vor Bio To Participate in Upcoming September Conferences
BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that management will partici...
Vor Bio price target raised to $27 from $18 at Wedbush
Wedbush raised the firm’s price target on Vor Bio (VOR) to $27 from $18 and keeps a Neutral rating on the shares. The firm notes the company reported earnings and…
Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Enrollment on track for Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis patients with topline results anticipated in 1H27 Enrollment ongoing for Phase 3 UPSTREAM SjD of teli...
Vor Biopharma Quarterly report: Q2 2026
Vor Biopharma has published its Q2 2026 quarterly earnings report on August 11, 2026.
Vor Biopharma Earnings release: Q2 2026
Vor Biopharma released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Vor Bio Appoints David Zaccardelli to Board of Directors
BOSTON, July 07, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of David Zacc...
Vor Bio announces China NMPA approval for telitacicept
Vor Bio (VOR) and RemeGen announced that China’s National Medicinal Products Administration, or NMPA, has conditionally approved telitacicept for the treatment of adult patients with IgAN.
Telitacicept Receives NMPA Approval for the Treatment of Sjögren's Disease in China
First regulatory approval for Sjögren's disease (SjD) First and only approved therapy for SjD in China Approval based on positive Phase 3 results generated by collaborator RemeGen demonstrating statis...
Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China
First and only approved BAFF/APRIL-targeting therapy for IgA nephropathy (IgAN) Approval based on positive interim Phase 3 TELIGAN results generated by collaborator RemeGen and recently published in ...
Vor Biopharma Transcript: Jefferies Global Healthcare Conference 2026
Telitacicept, a dual BAFF/APRIL inhibitor, is advancing through global phase III trials for gMG and Sjögren's, leveraging robust efficacy and safety data from China. Positioned for first- or second-line use in large, rapidly growing markets, the company maintains a strong cash runway and commercial focus.
Vor Bio to Participate in the 2026 Jefferies Global Healthcare Conference
BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will provide a corpora...
Vor Bio price target raised to $18 from $15 at Wedbush
Wedbush analyst Martin Fan raised the firm’s price target on Vor Bio (VOR) to $18 from $15 and keeps a Neutral rating on the shares. The firm notes the company…
Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine
Interim analysis demonstrated a 55.0% relative reduction in proteinuria versus placebo at 39 weeks with eGFR remaining stable through treatment Results further support the potential for telitacicept ...
Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
Enrollment on track for Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis patients with topline results anticipated in 1H27 Enrollment ongoing for Phase 3 UPSTREAM SjD of teli...
Vor Biopharma Quarterly report: Q1 2026
Vor Biopharma has published its Q1 2026 quarterly earnings report on May 13, 2026.